2025
-
Combination Therapies as Frontline Treatment for EGFR-Mutated NSCLC: Are the Rewards Worth the Risks?
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies.
-
With Data on Her Side, Dr. Anne Tsao Dominates Debate on Merits of Chemo-IO for Mesothelioma
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case.
-
Picking Up the Pieces: The Impact of the Western US Wildfires on Cancer Care
Dr. Karen Reckamp discusses the challenges that both patients and oncologists in the Los Angeles area experienced during the devastating fires.
-
Zipalertinib Meets Primary Endpoint in Phase 2b Trial
The drug’s developers have said the data show a positive overall response rate in previously treated patients with NSCLC with EGFR exon 20 insertion mutations.
-
Climate Change-Fueled Natural Disasters and the Impacts on Lung Cancer Care
In our continuing series on role the environment plays in thoracic oncology, Dr. Roselle De Guzman outlines the risks posed by our changing climate and the potential benefits of taking a proactive approach to reduce those risks.
-
Will Bispecific Antibodies Replace PD-(L)1 Targeted Agents?
Drs. Jonathan W. Riess and Greg Kalemkerian present opposing views regarding the therapeutic potential of novel targeted therapies.
-
Debate Leaves Audience Unconvinced that KRAS Inhibitors Deserve Promotion to First-Line Treatment
While Dr. Trever Bivona argued that KRAS inhibitors will join other seminal oncogene inhibitors, Dr. Rebecca Heist said the data has yet to demonstrate they outperform the current second-line standard of care.
-
Updated Data Show Median OS of 16.9 months in Patients with Advanced NSCLC Treated with THIO
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent.
-
US FDA Grants Priority Review for Zongertinib for Advanced HER2+ NSCLC
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients.
-
Healthcare Community Can Still Take Action to Combat Effects of Climate Change
Dr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes.
View ILCN Archives
Provider Resources